Nutex Health Reports Strong 2025 Results, 82% Revenue Growth, and Announces $25M Share Repurchase
NUTX sits 75% above its 52-week low of $40.67 on elevated volume (2.2× avg).
Summary
Nutex Health Inc. announced robust full-year 2025 financial results, including an 82.4% revenue increase and a 152.6% Adjusted EBITDA surge, alongside the remediation of material weaknesses and a new $25 million share repurchase program.
Key Events · Earnings and Guidance · NUTX
-
Strong Full-Year 2025 Financial Performance
Total revenue increased 82.4% to $875.3 million for 2025, with net income attributable to Nutex Health rising to $70.8 million from $52.1 million in 2024. Adjusted EBITDA surged 152.6% to $259.6 million.
-
Significant Cash Generation and Balance Sheet Strength
The company reported net cash from operating activities of $248.1 million for 2025, and cash and cash equivalents increased to $185.6 million as of December 31, 2025, up from $40.6 million in 2024.
-
Remediation of Material Weaknesses
Nutex Health successfully remediated all previously disclosed material weaknesses in internal controls over financial reporting during 2025, enhancing transparency and investor confidence.
-
New $25 Million Share Repurchase Program
The Board of Directors authorized a second stock repurchase program of up to $25.0 million of common stock over the next six months, aimed at increasing shareholder value and offsetting future dilution from stock compensation.
Analysis · NUTX · Trade & Services
Nutex Health Inc. reported exceptionally strong full-year 2025 financial results, with significant growth across key metrics including an 82.4% increase in total revenue and a 152.6% rise in Adjusted EBITDA. The company also generated substantial cash from operations and significantly boosted its cash reserves. A notable positive is the remediation of all previously disclosed material weaknesses in internal controls, enhancing investor confidence. While fourth-quarter reported revenue and Adjusted EBITDA showed declines, these were attributed to one-time arbitration claim adjustments and timing, with underlying adjusted revenue showing an increase. The announcement of a new $25 million share repurchase program, representing a substantial portion of the company's market capitalization, signals management's confidence and commitment to shareholder value.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NUTX was trading at $71.34 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $745M. The 52-week trading range was $40.67 to $193.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.